MOR News and Press, MorphoSys AG From 05/03/23

2023-05-03 17:37:36 ET MorphoSys press release ( NASDAQ: MOR ): Q1 GAAP EPS of -€1.30. Revenue of €62.3M (+50.1% Y/Y). Monjuvi ® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023. €79...

– Monjuvi ® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 &#x...

Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on Ma...

- Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), and Incyte (Nasdaq: INCY) today anno...

2023-04-13 08:01:47 ET Summary MorphoSys completed enrollment for MANIFEST-2, a Phase 3 study exploring the safety and efficacy of pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients with myelofibrosis. The topline data of the MANIFEST-2 is expected by...

2023-04-05 14:34:00 ET Shares of MorphoSys (NASDAQ: MOR) were up more than 16% Wednesday afternoon after the biopharmaceutical company updated the trials status of the company's lead therapy. The stock is up more than 28% so far this year. The company specializes in therapies to tre...

2023-04-05 11:58:46 ET MorphoSys AG ( NASDAQ: MOR ) added ~16% in the morning hours Wednesday after the German biotech indicated a faster-than-expected timeline for its ongoing late-stage study for experimental therapy, pelabresib, against blood cancer myelofibrosis. The com...

2023-03-16 11:11:16 ET The following slide deck was published by MorphoSys AG in conjunction with their 2022 Q4 earnings call. For further details see: MorphoSys AG 2022 Q4 - Results - Earnings Call Presentation

2023-03-16 11:10:09 ET MorphoSys AG (MOR) Q4 2022 Earnings Conference Call March 16, 2023, 8:00 AM ET Company Participants Julia Neugebauer - Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Development Officer ...

2023-03-15 16:20:36 ET MorphoSys press release ( NASDAQ: MOR ): FY GAAP EPS of €8.93. Revenue of €81.6M (+54.3% Y/Y). Monjuvi U.S. net product sales US$ 80m to 95m For further details see: MorphoSys GAAP EPS of €8.93, reven...